Impact of a Value-Based Formulary in Three Chronic Disease Cohorts

Research presented by Kai Yeung, PharmD, PhD, scientific investigator I, Group Health Research Institute, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Related Videos

Related Content

Advertisement

February 21st 2025

NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS

Rose McNulty

The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

February 20th 2025

Getting More Doctors to Record a Life-Saving Prostate Cancer Calculation

Mary Caffrey

Accurate calculation of prostate-specific antigen doubling time can be crucial for prostate cancer treatment decisions but is often missed by doctors, impacting patient care.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

February 19th 2025

Alcohol and Cancer Risk: Murthy’s Parting Call for Warning Labels

Maggie L. Shaw

February 18th 2025

Phase 1 Study Identifies Casdatifan Dose With Promising Responses in Pretreated Clear Cell RCC

Mary Caffrey

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell carcinoma (RCC).

Related Content

Advertisement

February 21st 2025

NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS

Rose McNulty

The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

February 20th 2025

Getting More Doctors to Record a Life-Saving Prostate Cancer Calculation

Mary Caffrey

Accurate calculation of prostate-specific antigen doubling time can be crucial for prostate cancer treatment decisions but is often missed by doctors, impacting patient care.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

February 19th 2025

Alcohol and Cancer Risk: Murthy’s Parting Call for Warning Labels

Maggie L. Shaw

February 18th 2025

Phase 1 Study Identifies Casdatifan Dose With Promising Responses in Pretreated Clear Cell RCC

Mary Caffrey

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell carcinoma (RCC).